Long-Term Renal and Cardiovascular Outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Participants by Baseline Estimated GFR

被引:61
作者
Rahman, Mahboob [1 ]
Ford, Charles E. [1 ]
Cutler, Jeffrey A. [1 ]
Davis, Barry R. [1 ]
Piller, Linda B. [1 ]
Whelton, Paul K. [1 ]
Wright, Jackson T., Jr. [1 ]
Barzilay, Joshua I. [1 ]
Brown, Clinton D. [1 ]
Colon, Pedro J., Sr. [1 ]
Fine, Lawrence J. [1 ]
Grimm, Richard H., Jr. [1 ]
Gupta, Alok K. [1 ]
Baimbridge, Charles [1 ]
Haywood, L. Julian [1 ]
Henriquez, Mario A. [1 ]
Ilamaythi, Ekambaram [1 ]
Oparil, Suzanne [1 ]
Preston, Richard [1 ]
机构
[1] Univ Texas Houston, Sch Publ Hlth, Houston, TX 77030 USA
来源
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2012年 / 7卷 / 06期
关键词
CHRONIC KIDNEY-DISEASE; BLOOD-PRESSURE CONTROL; HYPERTENSIVE PATIENTS; PROGRESSION; ASSOCIATION; AMERICAN; DESIGN;
D O I
10.2215/CJN.07800811
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background and objectives CKD is common among older patients. This article assesses long-term renal and cardiovascular outcomes in older high-risk hypertensive patients, stratified by baseline estimated GFR (eGFR), and long-term outcome efficacy of 5-year first-step treatment with amlodipine or lisinopril, each compared with chlorthalidone. Design, setting, participants, & measurements This was a long-term post-trial follow-up of hypertensive participants (n=31,350), aged >= 55 years, randomized to receive chlorthalidone, amlodipine, or lisinopril for 4-8 years at 593 centers. Participants were stratified by baseline eGFR (ml/min per 1.73 m(2)) as follows: normal/increased (>= 90; n=8027), mild reduction (60-89; n=17,778), and moderate/severe reduction (<60; n=5545). Outcomes were cardiovascular mortality (primary outcome), total mortality, coronary heart disease, cardiovascular disease, stroke, heart failure, and ESRD. Results After an average 8.8-year follow-up, total mortality was significantly higher in participants with moderate/severe eGFR reduction compared with those with normal and mildly reduced eGFR (P<0.001). in participants with an eGFR <60, there was no significant difference in cardiovascular mortality between chlorthalidone and amlodipine (P=0.64), or chlorthalidone and lisinopril (P=0.56). Likewise, no significant differences were observed for total mortality, coronary heart disease, cardiovascular disease, stroke, or ESRD. Conclusions CKD is associated with significantly higher long-term risk of cardiovascular events and mortality in older hypertensive patients. By eGFR stratum, 5-year treatment with amlodipine or lisinopril was not superior to chlorthalidone in preventing cardiovascular events, mortality, or ESRD during 9-year follow-up. Because data on proteinuria were not available, these findings may not be extrapolated to proteinuric CKD. Clin J Am Soc Nephrol 7: 989-1002, 2012. doi: 10.2215/CJN.07800811
引用
收藏
页码:989 / 1002
页数:14
相关论文
共 38 条
  • [1] Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis - A randomized controlled trial
    Agodoa, LY
    Appel, L
    Bakris, GL
    Beck, G
    Bourgoignie, J
    Briggs, JP
    Charleston, J
    Cheek, D
    Cleveland, W
    Douglas, JG
    Douglas, M
    Dowie, D
    Faulkner, M
    Gabriel, A
    Gassman, J
    Greene, T
    Hall, Y
    Hebert, L
    Hiremath, L
    Jamerson, K
    Johnson, CJ
    Kopple, J
    Kusek, J
    Lash, J
    Lea, J
    Lewis, JB
    Lipkowitz, M
    Massry, S
    Middleton, J
    Miller, ER
    Norris, K
    O'Connor, D
    Ojo, A
    Phillips, RA
    Pogue, V
    Rahman, M
    Randall, OS
    Rostand, S
    Schulman, G
    Smith, W
    Thornley-Brown, D
    Tisher, CC
    Toto, RD
    Wright, JT
    Xu, SC
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (21): : 2719 - 2728
  • [2] [Anonymous], 2004, Am J Kidney Dis, V43, pS1
  • [3] Antihypertensive T., 2002, JAMA-J AM MED ASSOC, V288, P2981, DOI [10.1001/jama.288.23.2981, DOI 10.1001/JAMA.288.23.2981]
  • [4] Intensive Blood-Pressure Control in Hypertensive Chronic Kidney Disease
    Appel, Lawrence J.
    Wright, Jackson T., Jr.
    Greene, Tom
    Agodoa, Lawrence Y.
    Astor, Brad C.
    Bakris, George L.
    Cleveland, William H.
    Charleston, Jeanne
    Contreras, Gabriel
    Faulkner, Marquetta L.
    Gabbai, Francis B.
    Gassman, Jennifer J.
    Hebert, Lee A.
    Jamerson, Kenneth A.
    Kopple, Joel D.
    Kusek, John W.
    Lash, James P.
    Lea, Janice P.
    Lewis, Julia B.
    Lipkowitz, Michael S.
    Massry, Shaul G.
    Miller, Edgar R.
    Norris, Keith
    Phillips, Robert A.
    Pogue, Velvie A.
    Randall, Otelio S.
    Rostand, Stephen G.
    Smogorzewski, Miroslaw J.
    Toto, Robert D.
    Wang, Xuelei
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (10) : 918 - 929
  • [5] Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: A meta-analysis
    Balamuthusamy, Saravanan
    Srinivasan, Lavanya
    Verma, Meenakshi
    Adigopula, Sasikanth
    Jalandara, Nishant
    Hathiwala, Suresh
    Smith, Earl
    [J]. AMERICAN HEART JOURNAL, 2008, 155 (05) : 791 - 805
  • [6] Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy
    Berl, T
    Hunsicker, LG
    Lewis, JB
    Pfeffer, MA
    Porush, JG
    Rouleau, JL
    Drury, PL
    Esmatjes, E
    Hricik, D
    Parikh, CR
    Raz, I
    Vanhille, P
    Wiegmann, TB
    Wolfe, BM
    Locatelli, F
    Goldhaber, SZ
    Lewis, EJ
    [J]. ANNALS OF INTERNAL MEDICINE, 2003, 138 (07) : 542 - 549
  • [7] Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
    Brenner, BM
    Cooper, ME
    de Zeeuw, D
    Keane, WF
    Mitch, WE
    Parving, HH
    Remuzzi, G
    Snapinn, SM
    Zhang, ZX
    Shahinfar, S
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) : 861 - 869
  • [8] Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
    Chobanian, AV
    Bakris, GL
    Black, HR
    Cushman, WC
    Green, LA
    Izzo, JL
    Jones, DW
    Materson, BJ
    Oparil, S
    Wright, JT
    Roccella, EJ
    [J]. HYPERTENSION, 2003, 42 (06) : 1206 - 1252
  • [9] Rationale and design for the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT)
    Davis, BR
    Cutler, JA
    Gordon, DJ
    Furberg, CD
    Wright, JT
    Cushman, WC
    Grimm, RH
    LaRosa, J
    Whelton, PK
    Perry, HM
    Alderman, MH
    Ford, CE
    Oparil, S
    Francis, C
    Proschan, M
    Pressel, S
    Black, HR
    Hawkins, CM
    [J]. AMERICAN JOURNAL OF HYPERTENSION, 1996, 9 (04) : 342 - 360
  • [10] The Chronic Renal Insufficiency Cohort (CRIC) study: Design and methods
    Feldman, HI
    Appel, LJ
    Chertow, GM
    Cifelli, D
    Cizman, B
    Daugirdas, J
    Fink, JC
    Franklin-Becker, ED
    Go, AS
    Hamm, LL
    He, JA
    Hostetter, T
    Hsu, CY
    Jamerson, K
    Joffe, M
    Kusek, JW
    Landis, JR
    Lash, JP
    Miller, ER
    Mohler, ER
    Muntner, P
    Ojo, AO
    Rahman, M
    Townsend, RR
    Wright, JT
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (07): : S148 - S153